Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Astellas Pharma Inc. (ALPMY) recently announced its intention to terminate its collaboration with Ambit Biosciences Corp. for the development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib. Astellas and Ambit will terminate the collaboration on Sep 3, 2013. As a result of the termination, Ambit will regain all rights to quizartinib and will continue with the phase III clinical trial program for the candidate.

Quizartinib is currently in a phase IIb clinical study and is being evaluated as monotherapy treatment for adults suffering from relapsed or refractory acute myeloid leukemia (AML). The candidate is also in two phase I studies in a combination treatment regimen with chemotherapy and as a maintenance therapy following transplant.

Astellas and Ambit’s agreement dates back to Dec 2009. The companies had collaborated to develop quizartinib for AML and other indications. The partnership had also aimed to focus on the development of a series of novel FLT3 inhibitors. Responsibilities and expenses for the development of quizartinib or any other product in the US and Europe were to be shared equally. As per the agreement, Ambit had received an upfront cash payment of $40 million and was entitled to receive up to $350 million on the achievement of pre-commercialization milestones.

Astellas decided to end the collaboration due to strategic reasons. Astellas carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. (LCI - Snapshot Report), WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report) and QLT Inc. (QLTI - Analyst Report) look more attractive. All three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%